You are here:
Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers
Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma after 3 or more treatment lines [ID6549]
Topic selection
Project information
Project documents
35154-Anitocabtagene-Autoleucel-for-Multiple-Myeloma-V1.0-DEC2024-NON-CONF.pdf
Back to top